biostudies-literatureUnknown15(2)Haeger APET imaging of neuroendocrine tumours (NET) is well established for staging and therapy follow-up. The short half-life, increasing costs, and regulatory issues significantly limit the availability of approved imaging agents, such as [⁶⁸Ga]Ga-DOTA-TATE. Al[¹⁸F]F-NOTA-Octreotide provides a similar biodistribution and tumour uptake, can be produced on a large scale and may improve access to precision imaging. Here we prospectively compared the clinical utility of [⁶⁸Ga]Ga-DOTA-TATE and Al[¹⁸F]F-NOTA-Octreotide in the Latin-American population. Our results showed that in patients with stage IV NETs [⁶⁸Ga]Ga-DOTA-TATE presents higher physiological uptake than Al[¹⁸F]F-NOTA-Octreotide in the liver, hypophysis, salivary glands, adrenal glands (all <i>p</i> &lt; 0.001), pancreatic uncinated process, kidneys, and small intestine (all <i>p</i> &lt; 0.05). Nevertheless, despite the lower background uptake of Al[¹⁸F]F-NOTA-Octreotide, comparative analysis of tumour-to-liver (TLR) and tumour-to-spleen (TSR) showed no statistically significant difference for lesions in the liver, bone, lymph nodes, and other tissues. Only three discordant lesions in highly-metastases livers were detected by [⁶⁸Ga]Ga-DOTA-TATE but not by Al[¹⁸F]F-NOTA-Octreotide and only one discordant lesion was detected by Al[¹⁸F]F-NOTA-Octreotide but not by [⁶⁸Ga]Ga-DOTA-TATE. Non-inferiority analysis showed that Al[¹⁸F]F-NOTA-Octreotide is comparable to [⁶⁸Ga]Ga-DOTA-TATE. Hence, our results demonstrate that Al[¹⁸F]F-NOTA-Octreotide provided excellent image quality, visualized NET lesions with high sensitivity and represents a highly promising, clinical alternative to [⁶⁸Ga]Ga-DOTA-TATE.Cancers439https://www.ebi.ac.uk/biostudies/studies/S-EPMC9856643biostudies-literatureAl[¹⁸F]F-NOTA-Octreotide Is Comparable to [⁶⁸Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population.PMC9856643Kramer VHurtado de Mendoza AEppard EEmmanuel NSoza-Ried CHaeger AFernandez RWettlin JAmaral HfalseAl[¹⁸F]F-NOTA-Octreotide Is Comparable to [⁶⁸Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population.PET imaging of neuroendocrine tumours (NET) is well established for staging and therapy follow-up. The short half-life, increasing costs, and regulatory issues significantly limit the availability of approved imaging agents, such as [⁶⁸Ga]Ga-DOTA-TATE. Al[¹⁸F]F-NOTA-Octreotide provides a similar biodistribution and tumour uptake, can be produced on a large scale and may improve access to precision imaging. Here we prospectively compared the clinical utility of [⁶⁸Ga]Ga-DOTA-TATE and Al[¹⁸F]F-NOTA-Octreotide in the Latin-American population. Our results showed that in patients with stage IV NETs [⁶⁸Ga]Ga-DOTA-TATE presents higher physiological uptake than Al[¹⁸F]F-NOTA-Octreotide in the liver, hypophysis, salivary glands, adrenal glands (all <i>p</i> &lt; 0.001), pancreatic uncinated process, kidneys, and small intestine (all <i>p</i> &lt; 0.05). Nevertheless, despite the lower background uptake of Al[¹⁸F]F-NOTA-Octreotide, comparative analysis of tumour-to-liver (TLR) and tumour-to-spleen (TSR) showed no statistically significant difference for lesions in the liver, bone, lymph nodes, and other tissues. Only three discordant lesions in highly-metastases livers were detected by [⁶⁸Ga]Ga-DOTA-TATE but not by Al[¹⁸F]F-NOTA-Octreotide and only one discordant lesion was detected by Al[¹⁸F]F-NOTA-Octreotide but not by [⁶⁸Ga]Ga-DOTA-TATE. Non-inferiority analysis showed that Al[¹⁸F]F-NOTA-Octreotide is comparable to [⁶⁸Ga]Ga-DOTA-TATE. Hence, our results demonstrate that Al[¹⁸F]F-NOTA-Octreotide provided excellent image quality, visualized NET lesions with high sensitivity and represents a highly promising, clinical alternative to [⁶⁸Ga]Ga-DOTA-TATE.2023-01-01T00:00:00Z2023 Jan2025-04-22T01:09:33.245Z2025-04-05T19:50:37.11ZS-EPMC98566433667238810.3390/cancers15020439